Medeor Therapeutics to Present Interim Pivotal Data on MDR-101 Cell Therapy for Induction of Immune Tolerance and Elimination of Immunosuppressants Following Kidney Transplant in Late Breaker Oral Presentation at ASN Kidney Week 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Medeor Therapeutics today announced that it will present interim Phase 3 data investigating if MDR-101 cell therapy can safely induce immune tolerance and eliminate the need for immunosuppressive drugs vs. standard of care following a kidney transplant as a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania.

Date/Time: Friday, November 3, 2023, 12:15pm
Presentation Title: MDR-101-MLK Update – Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients
Session Name: High-Impact Clinical Trials
Location: Hall A, Pennsylvania Convention Center, Philadelphia
Abstract Publication #: FR-OR115
Presenter: Daniel Brennan MD, Consultant, Medeor Therapeutics

About MDR-101

MDR-101 is a cellular therapy manufactured from a living kidney donor’s blood. MDR-101 is intended to induce donor-specific immune tolerance in order to avert transplanted kidney rejection and eliminate the cumulative and serious side effects associated with immunosuppressive drugs, and thereby preserve transplant kidney function and survival. For more information on Medeor’s phase 3 trial, please visit www.clinicaltrials.gov, (NCTT03363945).

About Medeor Therapeutics

Medeor Therapeutics is working to improve the lives of transplant patients by eliminating the need for a life-long regimen of immunosuppressant medications and their potential life-threatening side effects. Medeor’s Phase 3 clinical study demonstrates the significant opportunities of this one-time therapy. For more information, visit www.medeortx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231025066977/en/